Enterprise Value

81.31M

Cash

264.2M

Avg Qtr Burn

-19.11M

Short % of Float

18.42%

Insider Ownership

24.24%

Institutional Own.

75.39%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 1b

Data readout

Phase 1b

Data readout

ORIC-114 (EGFR/HER2 Inhibitor) Details
Solid tumor/s, Advanced malignancies

Phase 1b

Data readout

Failed

Discontinued

ORIC-101 (Glucocorticoid Receptor Antagonist) and nab-paclitaxel Details
Solid tumor/s, Spasticity, Muscle control disorder

Failed

Discontinued